

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Steinberg, Michael, B

eRA COMMONS USER NAME (credential, e.g., agency login): mbsteinberg

POSITION TITLE: Professor and Division Chief

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Rutgers College, New Brunswick, NJ	BA	05/1989	Biological Sciences
University of Medicine and Dentistry of NJ – School of Public Health; New Brunswick, NJ	MPH	05/1993	Health Educ/ Beh Sci
University of Medicine and Dentistry of NJ – Robert Wood Johnson Medical School; New Brunswick, NJ	MD	05/1994	Medicine

A. Personal Statement

I am honored to be part of the Rutgers Cancer Institute of New Jersey's (CINJ) CCSG application. I have been a member of CINJ for the past 22 years, participating in the research, clinical, and scholarly missions of the organization. Support from CINJ has enabled me to obtain independent funding from NCI and other sources for my research in tobacco control including PI of 2 NCI-funded R01 studies (R01CA190444-01A1: *Physicians' Perceptions, Attitudes, and Communication of E-Cigarettes (PACE)* and R01CA260831-01-A1 Evaluating Cigarette Relighting Behaviors: Prevalence, Predictors, and Toxin Exposure). Over the past 22 years, I have been an active member of the Cancer Prevention and Control (CPC) Program as well as the Clinical Investigations and Precision Therapeutics (CIPT) Program. I have also participated in other CINJ Cancer Prevention activities, such as a founding member of the SCREEN NJ program, developed to increase cancer screening across the state.

With CINJ's support, I also served as Director of the Rutgers Center for Tobacco Studies' Certified Tobacco Treatment Specialist Training Program since the early 2000's; one of a handful of accredited Certified Tobacco Treatment Specialist Training Programs in North America to train healthcare professionals on evidence-based tobacco treatment skills. We have trained over 8,000 healthcare professionals from 48 states and 25 countries. As Medical Director of the Rutgers Center for Tobacco Studies, we have run a tobacco treatment program which has treated nearly 10,000 tobacco users with this deadly addiction.

Ongoing and recent projects I would like to highlight include:

R01CA260831-01-A1

Steinberg/Heckman/Stepanov MPI

02/2022–01/2026

Evaluating Cigarette Relighting Behaviors: Prevalence, Predictors, and Toxin Exposure

NCI

P30CA072720

Libutti PI

9/2020-8/2022

Enhancement and Expansion of the C3I Program to develop tobacco cessation treatment capacity and infrastructure for cancer patients Cancer Centers

NCI

Role: Project Lead

R01CA190444-01A1

Delnevo/Steinberg MPI

6/2016-5/2022

Physicians' Perceptions, Attitudes, and Communication of E-Cigarettes (PACE)

NCI

The combination of my broad clinical experience as a physician and research background with tobacco treatment studies will allow me to continue to support the mission of CINJ.

B. Positions, Scientific Appointments, and Honors

Positions and Scientific Appointments

2020- Project Lead Rutgers CINJ; NCI C3I Initiative
2020- Population Subgroup Chair - RBHS Research Strategic Plan Committee
2019- Medical Director; Rutgers Center for Tobacco Studies
2019- Chair; RWJMS Appointment and Promotions Committee
2019- Penn-Rutgers Tobacco Center of Regulatory Science External Scientific Advisory Board
2018- Member, RWJMS School-wide Research Committee
2018- RWJMS/NJMS Academic Chief of Cardiology Search Committee Chair
2018- CINJ Screen NJ Steering Committee
2017- Vice-Chair for Clinical Research; Department of Medicine; Rutgers RWJ Medical School
2015- Professor & Division Chief, General Internal Medicine; Rutgers RWJ Medical School
2014-15 Consultant; American College of Physicians' E-cigarette Position Statement
2010- Director; Rutgers Tobacco Dependence Program
2010- Board of Directors; Association for the Treatment of Tobacco Use and Dependence
2010-14 Commissioner, ATTUD Training Program Accreditation Commission
2007- Editorial Board; *HemeOnc Today*
2005- Certified Tobacco Treatment Specialist (CTTS)
2002- Society for Research on Nicotine and Tobacco
2001- Cancer Institute of New Jersey
2001-10 Lung Cancer Workgroup of the Task Force on Cancer Prevention, Early Detection, Treatment in NJ
1997- Society of General Internal Medicine
1994- American College of Physicians

Honors

2022 Elected to NJ ACTS (Alliance for Clinical and Translational Science) Academy of Mentors
2022 Rutgers College Class of 1930 Ernest E. McMahon Award - The award is named in honor of Ernest E. McMahon (RC '30) who was a dean of University College, dean of the University Extension Division, and director of the Institute of Management and Labor Relations, and who demonstrated a commitment to extending the mission of Rutgers to new populations. In the spirit of Ernest McMahon, this award is given to an individual or a group within Rutgers University that has made a significant and creative contribution to the extension of the educational resources of the university to the people of New Jersey through such means as continuing education or extramural programs.
2021 Food, Drug, and Law Institute; Invited speaker; Understanding Nicotine: Health Impacts, Public Misperceptions, and Improving Education; April 2021
2021- NJ Magazine Top Internists in NJ 2021
2011-14 President; Association for the Treatment of Tobacco Use and Dependence
2010- Elected as *Fellow* of the American College of Physicians (FACP)
2007- Selected to *Best Doctors in America* 2007-8; 2009-10; 2011-12; 2012-13, 2015-16, 2016-17
2006-09 Robert Wood Johnson Foundation Physician Faculty Scholars Program

2003, 04 Excellence in Teaching Award; Department of Medicine, Robert Wood Johnson Medical School
1996, 97 Outstanding Teaching Resident Award; Thomas Jefferson University Hospital
1995 Intern of the Year; Department of Medicine, Thomas Jefferson University Hospital

C. Contributions to Science

1) Advances in Tobacco Treatment Methods.

Below are some of the pioneering studies regarding tobacco treatment interventions among various populations including the first trial of a triple-combination pharmacotherapy regimen in medically-ill smokers, the first trial of varenicline among hospitalized smokers, the first comparison of an FDA-approved pharmacotherapy, nicotine inhaler, and an ENDS product, and the first narrative review of the effectiveness of group treatment for tobacco dependence.

- a. **Steinberg MB**, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, Carson JL. Triple Combination Pharmacotherapy for Medically-Ill Smokers. *Ann Int Med.* 2019; 150(7):447-54. PMID: 19349630
- b. **Steinberg MB**, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL. Tobacco Dependence Treatment for Hospitalized Smokers: A Randomized, Controlled, Pilot Trial Using Varenicline. *Addictive Behaviors.* 2011; 36:1127-32. PMID: 21835552
- c. **Steinberg MB**, Zimmermann MH, Lewis MJ, Delnevo CD, Shukla P, Coups E, Foulds J. Comparing the Perceptions and Experiences of Inhaled Nicotine Devices: E-cigarette vs. Nicotine Inhaler. *J Gen Int Med.* 2014; 29(11): 444-50. PMID: 24830741; PMCID: PMC4238186
- d. Kotsen C, Santorelli ML, Bloom EL, Goldstein AO, Ripley-Moffitt C, **Steinberg MB**, Burke MV, Foulds J. A Narrative Review of Intensive Group Tobacco Treatment: Clinical, Research, and US Policy Recommendations. *Nicotine Tob Res.* 2019; 21(12):1580-1589. PMID: 30124924

2) Impact of changing tobacco marketplace on physicians' knowledge and practices regarding tobacco treatment.

I have been exploring how the impact of changes in the tobacco product market (e.g., emergence of e-cigarettes) might impact physician knowledge and practices regarding tobacco treatment and cessation.

- a. **Steinberg MB**, Giovenco DP, Delnevo CD. Patient-physician communication regarding electronic cigarettes. *Prev Med Rep.* 2015; 2:96-8. PMID: 26844056; PMCID: PMC4721470
- b. Singh B, Hrywna M, Wackowski OA, Delnevo CD, MJ Lewis, **Steinberg MB**. Knowledge, recommendation, and beliefs of e-cigarettes among physicians involved in tobacco cessation: A qualitative study. *Prev Med Rep.* 2017; 8:25-29. PMID: 28831370; PMCID: PMC5555092
- c. Briganti M, Wackowski OA, Delnevo CD, Brown L, Hastings SE, Singh B, Steinberg MB. Content Analysis of Electronic Nicotine Delivery System Publications in Core Clinical Journals from 2012 to 2018. *Int J Environ Res Public Health.* 2020 Mar 25; 17(7):2201. PMID: 32218306; PMCID: PMC7177383
- d. Schaer DA, Singh B, **Steinberg MB**, Delnevo CD. Tobacco Treatment Guideline Use and Predictors Among U.S. Physicians by Specialty. *Am J Prev Med.* 2021; 61(6):882-889. PMID: 34364726; PMCID: PMC8608714 (available on 2022-12-01)

3) Physicians' perceptions of effectiveness of tobacco treatments.

I have also evaluated how healthcare providers perceive the effectiveness of tobacco treatment methods and implement evidence-based practices into their healthcare delivery.

- a. **Steinberg MB**, Zimmermann MH, Gundersen DA, Hart C, Delnevo CD. Physicians' Perceptions Regarding Effectiveness of Tobacco Cessation Medications. *Preventive Medicine.* 2011; 53(6):433-4. PMID: 22001686
- b. **Steinberg MB**, Delnevo CD. Physician Beliefs Regarding Effectiveness of Tobacco Dependence Treatments. *Journal of General Internal Medicine.* 2007; 22(10):1459-62. PMID: 17726636; PMCID: PMC2305846
- c. **Steinberg MB**, Nanavati K, Delnevo CD, Abatemarco DJ. Predictors of Self-reported Discussion of

Cessation Medications by Physicians in New Jersey. *Addictive Behaviors*. 2007; 32(12):3045-53. PMID: 17825495

- d. **Steinberg MB**, Alvarez MS, Delnevo CD, Kaufman I, Cantor JC. Disparity of Physicians' Utilization of Tobacco Treatment Services. *Am J Health Behaviors*. 2006; 30(4):375-386. PMID: 16787128

4) Predictors of successful tobacco cessation advances in tobacco dependence treatment methods.

I have examined various predictors of success in tobacco cessation as a way to advance the development of future interventions. These have included demographic characteristics, such as age and gender; co-morbidities and smoking behavior aspects, such as type of cigarette smoked (e.g., menthol) and relapse patterns.

- a. **Steinberg MB**, Akincigil A, Delnevo CD, Crystal S, Carson JL. Gender and age disparities for tobacco dependence treatment: Results of the 2001-2002 National Ambulatory Medical Care Survey. *Am J Prev Med*. 2006; 30(5):405-12. PMID: 16627128
- b. **Steinberg MB**, Bover MT, Richardson DL, Schmelzer AC, Williams JM, Foulds J. Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. *Drug and Alcohol Dependence*. 2011; 114:77-81. PMID: 20951511
- c. Delnevo CD, Gundersen DA, Hrywna M, Echeverria SE, **Steinberg MB**. Smoking-Cessation Prevalence Among U.S. Smokers of Menthol Versus Non-Menthol Cigarettes. *Am J Prev Med*. 2011; 41(4):357-65. PMID: 21961462
- d. Zimmermann MH, Richardson DL, Bover Manderski MT, Delnevo CD, **Steinberg MB**. Relighting behaviour among cigarette smokers seeking treatment: implications for tobacco treatment and policy. *Int J Clin Pract*. 2014; 68(11):1358-63. PMID: 25113663 PMID: PMC5270767

Complete listing of my bibliography can be found in MyBibliography:
<https://www.ncbi.nlm.nih.gov/myncbi/michael.steinberg.1/bibliography/public/>